Optimizing heart failure treatment in elderly patients with kidney issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of sodium zirconium cyclosilicate (SZC) in enabling elderly patients with heart failure and chronic kidney disease to receive optimal doses of renin-angiotensin aldosterone system inhibitors (RAASi) without causing significant hyperkalemia. The study is a randomized, multicenter, parallel group, open-label design, where participants will be assigned to receive either SZC or standard care for three months. The goal is to assess whether the use of SZC can help stabilize serum potassium levels and allow for the up-titration of RAASi therapies according to established clinical guidelines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Provision of informed consent form prior to any study specific procedures, sampling and analysis.
* Individuals must be ≥ 70 years of age at the time of signing the informed consent form.
* Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines NYHA functional class I-III (with HFrEF or HFpEF).
* Individuals must have previously been admitted to hospital due to HF decompensation requiring intravenous diuretics.
* Individuals must have been stabilised for at least 24-48h of their HF decompensation before randomisation.
* Individuals must have a confirmed diagnosis of Chronic Kidney Disease defined as a renal impairment of eGFR less than 60ml/min/1.73 m2.
* Individuals receiving background standard of care for HF and treated according to international guidelines. Specific treatment should include RAASi and/or MRA treatment and at least should have been stable for ≥ 4 weeks at maximum tolerated doses.
* Patients on RAASi blocker treatment with less than or equal to 75% of the maximum recommended dose.
* Hyperkalemic patients (sK+ 5.1-5.9 mmol/L at screening / study enrolment) or Normokalemic patients at risk of developing HK defining as having a history of hyperkalaemia (sK+ \>5.0 mEq/L) within the prior 24 months and sK+ ≥4.5 mEq/L ≤ 5.1 mEq/L at inclusion

Exclusion Criteria:

* Limited life expectancy (less than 1 year) according to clinician's criteria, such as but not limited to malignancy, with life expectancy of less than 2 years based on investigator's clinical judgement.
* sK \>6 mEq/litre or \<4.5mEq/litre or history of hypokalemic episodes (S-K\<3.5 mEq/L) during the last year.
* Patients on haemodialysis or haemofiltration
* NYHA functional class IV
* Patients undergoing treatment with potassium binders.
* Active tumour undergoing chemotherapy or metastasis or malignancy requiring treatment.
* Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted.
* QTc(f) \> 550 msec.
* History of QT prolongation associated with other medications that required discontinuation of that medication.
* Congenital long QT syndrome.
* Prior history of hypersensitivity to a RAAS blocker drug, including but not limited to development of angioedema, icterus, hepatitis, or neutropenia or thrombocytopenia requiring treatment modification. Addison's disease or other causes of hypoaldosteronism.
* Patients with a known hypersensitivity to SZC or any of the excipients of the product.
* Individuals treated with potassium binding resins such as sodium polystyrene sulfonate (SPS, e.g. Kayexalate®) or calcium polystyrene sulfonate (CPS; e.g. Resonium®) or the cation exchange polymer, patiromer sorbitex calcium (Veltassa®) within 7 days prior to the first dose of study drug.
* Treated with potassium supplements within 7 days prior to randomization. 15. Positive hepatitis C antibody hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening.
* Known to have tested positive for human immunodeficiency virus.
* Known history of drug or alcohol abuse within 3 year of screening.
* Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
* Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
* Previous enrolment in the present study.
* Participation in another clinical study with an investigational product during the last 3 months.

Where it's running

• Hospital Universitario Nuestra Señora del Perpétuo Socorro
  Albacete, Spain Recruiting
• Hospital Universitario de Burgos
  Burgos, Spain Recruiting
• Hospital Clínico Universitario de Valencia
  Valencia, Spain Recruiting
• Hospital Universitario Fundación Alcorcón
  Alcorcón, Madrid, Spain Not yet recruiting
• Hospital Universitario Severo Ochoa
  Leganés, Madrid, Spain Not yet recruiting
• Hospital Universitario Reina Sofía
  Córdoba, Spain Not yet recruiting

Study contacts

• Study coordinator: Clara Bonanad Lozano
• Email: clarabonanad@gmail.com
• Phone: +34 963156181

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Comparing two diabetes medications, empagliflozin and dapagliflozin

  This study is testing which diabetes medication, empagliflozin or dapagliflozin, works better for people with type 2 diabetes, chronic kidney disease, and heart failure.

  Recruiting at 12 sites Phase 4 Herlev and Gentofte Hospital · Copenhagen and 11 other locations · NCT06642272

• App to support post-hospital care for people with multiple chronic conditions

  This trial will test a smartphone/tablet app to help people aged 55+ with heart failure, diabetes, or chronic kidney disease manage their care after leaving the hospital.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06051058

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Research on health inequality and genetic disparity in cardiovascular diseases

  This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.

  Recruiting Future Genetics Limited · Wolverhampton, West Midlands · NCT03987633

• Hospital-level care delivered at home for acutely ill adults

  This trial tries to deliver hospital-level care at home to adults with sudden illnesses like infections, heart failure, COPD, asthma, or gout flares to see if it's as safe, improves patient experience, and lowers costs.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT03524222

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.